Skip to main content

Oral Integrin Deal Benchmarks in Immunology & Autoimmune

Median Upfront
$629M
Range: $334M - $911M
Total Deal Value
$3.3B
Range: $2.0B - $4.5B
Royalty Rate
14.4% - 23.9%
Tiered up to 27.9%
Dev Milestones
$531M
Range: $340M - $724M
Model Your Deal

Market Analysis

Oral Integrin therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 oral integrin asset in immunology & autoimmune is $629M, with total deal values reaching $3.3B. Development milestones average $531M, while regulatory milestones contribute $929M.

The immunology & autoimmune oral integrin landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for oral integrin immunology & autoimmune deals range from 14.4% to 23.9% at the base tier, with tiered escalation reaching 18.4%-27.9% on blockbuster sales. Commercial milestones averaging $1.2B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a oral integrin immunology & autoimmune licensing deal?
Based on our analysis, Phase 2 oral integrin licensing deals in immunology & autoimmune average $629M in upfront payments, with a range of $334M to $911M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for oral integrin immunology & autoimmune transactions?
The median total deal value for Phase 2 oral integrin assets in immunology & autoimmune is $3.3B, ranging from $2.0B to $4.5B. This includes development milestones ($531M), regulatory milestones ($929M), and commercial milestones ($1.2B).
What royalty rates are standard for oral integrin deals in immunology & autoimmune?
Base royalty rates for oral integrin immunology & autoimmune transactions range from 14.4% to 23.9%, with tiered escalations reaching 18.4%-27.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in oral integrin immunology & autoimmune deals?
Oral Integrin immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($531M) make up the largest share, followed by commercial milestones ($1.2B) and regulatory milestones ($929M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

Oral Integrin in Gastroenterology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included